Cell and Gene Therapy Today—June 25, 2026

LucidQuest

3 hours ago

This week’s Gene and Cell Therapy update highlights regulatory progress, pivotal trial advancement, early clinical data, platform innovation, and expanding cell therapy activity across rare diseases and oncology.

In Today’s Newsletter

Dive deeper

🧬 NAVSUNLI BLA resubmission path for MPS II [1] [US • 22 Jun 2026]

https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-alignment-fda-path-forward-navsunlitm-bla
Context: FDA said no additional studies or patients are needed, and REGENXBIO expects a Type A meeting in July and BLA resubmission in Q3 2026.
Key point: REGENXBIO said FDA aligned on a path for NAVSUNLI (clemidsogene lanparvovec-sngl, RGX-121) BLA resubmission for accelerated approval.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 AMT-130 BLA plan in Huntington’s disease [2] [US • 17 Jun 2026]

https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons
Context: FDA seeks alignment on a confirmatory study design before submission; uniQure plans a Q3 2026 BLA submission.
Key point: uniQure said FDA agreed the AMT-130 3-year Phase 1/2 analysis can serve as the primary basis for an accelerated approval BLA.
Implication: May influence prescriber choice and payer reviews pending full data.

⚡ AMT-260 early epilepsy data [3] [19 Jun 2026]

https://www.uniqure.com/investors-media/press-releases
Context: In the first low-dose cohort, 3 of 6 patients had 79%–100% reductions in disabling seizures during months 4–6; no related SAEs were reported.
Key point: uniQure reported preliminary six-month data for AMT-260 in refractory mesial temporal lobe epilepsy.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ ATSN-201 pivotal dosing in XLRS [4] [North America, EU • 22 Jun 2026]

https://atsenatx.com/press-release/atsena-therapeutics-doses-first-patient-and-reports-rapid-early-enrollment-in-pivotal-trial-of-atsn-201-for-x-linked-retinoschisis/
Context: Enrollment began in May; completion is expected in Q1 2027, topline results in 1H 2028, and BLA filing in 2H 2028.
Key point: Atsena Therapeutics dosed the first patient in the Phase 3 pivotal cohort of LIGHTHOUSE for ATSN-201 in X-linked retinoschisis.
Implication: May influence prescriber choice and payer reviews pending full data.

🧾 Genprex Canadian patent allowance [5] [Canada • 22 Jun 2026]

https://www.prnewswire.com/news-releases/genprex-receives-a-notice-of-allowance-from-the-canadian-intellectual-property-office-for-a-patent-claiming-the-combination-of-reqorsa-gene-therapy-with-either-pd-1-or-pd-l1-antibodies-to-treat-cancer-302804049.html
Context: The patent covers use in NSCLC and SCLC and supports combinations being evaluated in the Acclaim-3 trial with Tecentriq.
Key point: Genprex received a Canadian Notice of Allowance covering Reqorsa (quaratusugene ozeplasmid) with PD-1 or PD-L1 antibodies.
Implication: Signals pipeline investment and modality expansion.

🧒 First Cockayne syndrome gene therapy treatment [6] [US • 22 Jun 2026]

https://www.prnewswire.com/news-releases/first-patient-in-the-world-treated-with-gene-therapy-for-cockayne-syndrome-302805839.html
Context: Treatment occurred on 21 Apr 2026 at NewYork-Presbyterian Komansky Children’s Hospital; the therapy delivers ERCC8/CSA to the brain.
Key point: Riaan Research Initiative said a 6-year-old patient received the first experimental AAV9 gene therapy for Cockayne syndrome.
Implication: Signals pipeline investment and modality expansion.

🧬 BEAM-304 IND clearance in PKU [7] [US • 18 Jun 2026]

https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-clearance-investigational-new-drug-0
Context: The planned Phase 1/2 trial will first evaluate safety, tolerability, blood Phe reduction, and diet liberalization in patients with the R408W mutation.
Key point: Beam Therapeutics said FDA cleared the IND for BEAM-304, a base-editing program for phenylketonuria.
Implication: Signals pipeline investment and modality expansion.

🧠 TSHA-102 Rett syndrome pivotal update [8] [US • 22 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/22/3315248/0/en/taysha-gene-therapies-announces-completion-of-dosing-in-reveal-pivotal-trial-and-reports-longer-term-clinical-data-from-part-a-of-reveal-phase-1-2-trials-evaluating-tsha-102-for-re.html
Context: REVEAL pivotal dosed 17 patients; TSHA-102 was generally well-tolerated with no treatment-related SAEs or DLTs across N=29 as of June 2026.
Key point: Taysha completed dosing in the REVEAL pivotal trial and reported longer-term TSHA-102 data in Rett syndrome.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Satri-cel China approval in solid tumors [9] [China • 22 Jun 2026]

https://www.biospace.com/press-releases/carsgen-announces-approval-of-satri-cel-the-worlds-first-car-t-cell-therapy-product-for-solid-tumors
Context: The indication covers patients who failed at least two prior lines of therapy; CARsgen describes satri-cel as the first approved CAR T-cell therapy for solid tumors.
Key point: CARsgen said China’s NMPA approved satri-cel for Claudin18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma.
Implication: Introduces competition that may affect pricing and formulary access.

🎯 TECELRA full FDA approval and label expansion [10] [US • 22 Jun 2026]

https://www.prnewswire.com/news-releases/us-worldmeds-receives-full-us-fda-approval-of-tecelra-afamitresgene-autoleucel-with-an-expanded-indication-extending-the-first-approved-engineered-t-cell-therapy-for-a-solid-tumor-to-children-as-young-as-12-302806599.html
Context: SPEARHEAD-1 included 137 patients; TECELRA had a 43.8% ORR, 3.6% complete response rate, and median duration of response of 5.3 months.
Key point: US WorldMeds said FDA granted full approval for TECELRA (afamitresgene autoleucel) and expanded use to eligible patients aged 12+.
Implication: Introduces competition that may affect pricing and formulary access.

Why it matters

FDA accelerated-approval pathways remain central for rare neurogenetic programs, including NAVSUNLI and AMT-130.
Multiple programs are moving from early efficacy signals toward pivotal or BLA-enabling plans.
Cell therapy momentum in solid tumors expanded across China and the US, with satri-cel and TECELRA.
Platform approaches are becoming more visible, including Beam’s mutation-specific base-editing plan for PKU.
Patient-led rare disease development remains active, highlighted by the Cockayne syndrome first-in-human treatment.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Cell and Gene Therapy news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is NAVSUNLI, and what changed for REGENXBIO?

NAVSUNLI (REGENXBIO; clemidsogene lanparvovec-sngl, RGX-121) is a proposed one-time gene therapy for MPS II. FDA said existing clinical data can be considered for accelerated approval and no additional studies are required before resubmission. [1]

What did FDA tell uniQure about AMT-130?

FDA told uniQure that the 3-year Phase 1/2 analysis of AMT-130 can serve as the primary basis for an accelerated approval BLA in Huntington’s disease. Confirmatory study details still need alignment before submission. [2]

What were the early AMT-260 findings?

uniQure reported that 3 of 6 low-dose patients had meaningful seizure reductions during months 4–6 in refractory mesial temporal lobe epilepsy. The company also reported no related SAEs to date. [3]

What is ATSN-201’s pivotal timeline?

Atsena dosed the first patient in the Phase 3 LIGHTHOUSE pivotal cohort for ATSN-201 in XLRS. Enrollment is expected to finish in Q1 2027, with topline results in 1H 2028. [4]

Why is satri-cel notable?

CARsgen said satri-cel is the first approved CAR T-cell therapy for solid tumors. China’s NMPA approved it for later-line Claudin18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma. [9]

What changed for TECELRA?

US WorldMeds said TECELRA received full FDA approval and an expanded indication for biomarker-eligible patients aged 12+ with unresectable or metastatic synovial sarcoma after prior chemotherapy. [10]

Entities / Keywords

REGENXBIO, NAVSUNLI, clemidsogene lanparvovec-sngl, RGX-121, CAMPSIITE, MPS II, Hunter syndrome
uniQure, AMT-130, Huntington’s disease, RMAT, Breakthrough Therapy, Fast Track
uniQure, AMT-260, refractory mesial temporal lobe epilepsy, MTLE
Atsena Therapeutics, ATSN-201, LIGHTHOUSE, X-linked retinoschisis, XLRS
Genprex, Reqorsa, quaratusugene ozeplasmid, PD-1, PD-L1, Tecentriq, Acclaim-3, NSCLC, SCLC
Riaan Research Initiative, Cockayne syndrome, AAV9, ERCC8, CSA, UMass Chan, Weill Cornell Medicine
Beam Therapeutics, BEAM-304, phenylketonuria, PKU, base editing, PAH, R408W, lipid nanoparticle, LNP
Taysha Gene Therapies, TSHA-102, REVEAL, ASPIRE, Rett syndrome, intrathecal AAV gene therapy
CARsgen, satri-cel, satricabtagene autoleucel, Claudin18.2, gastric cancer, GEJ adenocarcinoma, NMPA
US WorldMeds, TECELRA, afamitresgene autoleucel, synovial sarcoma, MAGE-A4, HLA-A*02, SPEARHEAD-1